CHaapamaki Profile Banner
Carola Haapamäki Profile
Carola Haapamäki

@CHaapamaki

Followers
63
Following
783
Media
2
Statuses
35

Colorectal surgeon, PhD

Helsinki, Finland
Joined September 2018
Don't wanna be here? Send us removal request.
@BJSurgery
BJS
15 days
Factors influencing locoregional recurrence rates in locally advanced rectal cancer after total neoadjuvant treatment versus chemoradiotherapy in the RAPIDO trial ➡️ https://t.co/WvgTEZvwft The difference in LRR between TNT and CRT mainly occurred in patients treated with
0
77
164
@BjsOpen
BJS Open
27 days
Management and risk factors for colonic volvulus: retrospective national cohort study ➡️ https://t.co/sXf9zkxxTe Surgery should be recommended for colonic volvulus where co-morbidity, patient preference, and functional status allows. Surgically unfit patients have poorer
0
13
16
@CHaapamaki
Carola Haapamäki
1 month
The results of the ALASCCA RCT, showing lower recurrence rate after adjuvant aspirin in patients with local CRC and PIK3CA mutations in exon 9 or 20, are published. As the PI in Finland I’d like to thank all collaborators at Meilahti and Jorvi Hospitals (Helsinki University
@NEJM
NEJM
1 month
In patients with localized colorectal cancer and PIK3CA hotspot mutations in exon 9 or 20, daily low-dose aspirin resulted in a significantly lower recurrence rate than placebo. ALASCCA phase 3 trial results: https://t.co/c5FAYCmKwI Editorial: An Aspirin a Day for Improved
0
1
3
@GillSharlene
Sharlene Gill, MD, MPH, MBA, FASCO
9 months
#GI25 drawing to a close @ASCO Congrats to organizers & presenters 👏 🌟 My top 3 picks for practice-changing trials 👉all in #CRCsm molecularly defined subsets 🎯 🌟 CM8HW in dMMR mCRC @TheLancet 🌟BREAKWATER in BRAFV600E mCRC @NatureMedicine @skopetz 🌟 ALASCCA in
1
8
22
@CHaapamaki
Carola Haapamäki
9 months
Well done Anna! Proud to have participated in this trial with my team at Helsinki University Hospital, Colorectal Unit
@jgong15
Jun Gong
9 months
@Annamartling rand dbl-blind ALASCCA trial of adjuvant aspirin 160 mg daily x3 yrs in resected stage I-III #rectal or II-III #colon cancer ➡️ 37% screened had #PI3K alt w/reduced #CRC recurrence (HR 0.42-0.49) vs placebo. 50% got adj chemo for colon cancer #GI25 @OncoAlert
0
0
0
@iss_sic
International Society of Surgery (ISS/SIC)
1 year
Introducing our new ISS/SIC President, Ari K. Leppäniemi! 🎉 We are thrilled to have his leadership guiding us forward. Read more https://t.co/fCNAknvYOi 🌍💼 #isssic #Leadership #GlobalImpact #SurgeryExcellence
0
3
7
@SWexner
Steven D Wexner MD, PhD
1 year
Great interactive discussion during the @escp_tweets #ESCP24 Women’s Breakfast Symposium led by @GabrielleVanRam @marianaberho
2
10
43
@CHaapamaki
Carola Haapamäki
1 year
presentation of our upcoming PROSPERITY trial at #escp2024 by @LauraKoskenvuo @villesallinen @Adductor
1
4
6
@DCRjournal
DCRjournal
2 years
#DCRJournal visual abstract: Local Regrowth and the Risk of Distant Metastases Among Patients Undergoing Watch-and-Wait for Rectal Cancer: What Is the Best Control Group? Multicenter Retrospective Study: https://t.co/SjMTBdoL7W @Swexner @me4_so @ACPGBI @drtracyhull @ASCRS_1
2
23
68
@LauraKoskenvuo
Laura Koskenvuo
2 years
Our MOBILE2 trial is finally out in @JAMASurgery Oral antibiotics are beneficial, with no doubt, prior anterior rectal resection! Huge thanks to all our team! @villesallinen @CHaapamaki
@JAMASurgery
JAMA Surgery
2 years
Double-blinded MOBILE2-trial found that mechanical bowel preparation and oral antibiotics reduced the rate of overall morbidity, surgical site infections and anastomotic leaks compared to mechanical bowel preparation only prior anterior rectal resection. https://t.co/1mVNqwWmMx
1
16
40
@SeanLangenfeld
Sean Langenfeld
2 years
The 2023 @ASCRS_1 Clinical Practice Guidelines for #RectalCancer just dropped in the Jan '24 @DCRjournal issue. So much hard work went into this from all authors. Topics covered in depth: -TNT -Watch-and-wait -TaTME -Mgmt intraperitoneal rectal cancers https://t.co/crhRH1t6Qs
3
98
254
@CHaapamaki
Carola Haapamäki
3 years
Looking forward to the meeting! @LauraKoskenvuo @LauraRenkonen
0
0
1
@LauraKoskenvuo
Laura Koskenvuo
4 years
Nordic Peritoneal Oncology Group meeting 2022.@CHaapamaki @Adductor Very nice to meet everybody in person after two years with online meetings only
0
2
7
@CHaapamaki
Carola Haapamäki
4 years
0
0
0
@ProfLiitto
Professoriliitto
4 years
Tänään vetoamme päättäjiin maamme suurimmissa sanomalehdissä. Suomella ei ole varaa leikata tutkimuksesta ja koulutuksesta. Suunnitellut tiedeleikkaukset on peruttava budjettiriihessä. @okmfi @valtioneuvosto @MarinSanna @kurvisentwiit @liandersson #tiede #tutkimus #budjettiriihi
6
114
478
@LauraKoskenvuo
Laura Koskenvuo
4 years
Protocol of our #MOBILE2 trial comparing MOABP (Mechanical and Oral Antibiotic Bowel Preparation) vs. MBP (Mechanical Bowel Preparation) in rectal resections @villesallinen @CHaapamaki @BMJ_Open @LunkkaPipsa
0
4
16
@ColorectalDis
Colorectal Disease
5 years
The 🌟Retro-Rectal Tumour🌟. How do you manage them? What factors are associated with malignancy? @ACPGBI @Dukes_Club @escp_tweets Study: Clinical management of 52 consecutive retro‐rectal tumours treated at a tertiary referral centre
0
6
24
@CHaapamaki
Carola Haapamäki
5 years
Virtually relaxed #ESCP2020 #ESCP2020COMP
0
2
11
@DCRjournal
DCRjournal
5 years
Low Anterior Resection Syndrome (LARS) after TaTME (Bottom-Up) vs. Conventional (Top-to-Bottom) Approach: https://t.co/Sm723G240A #ColorectalResearch @JISBMD @ConorDelaneyMD @justinmaykel @dubaicolorectal @SamAtallahMD @JohnRTMonsonMD @Swexner @ACPGBI @drtracyhull @ASCRS_1
1
34
55
@escp_tweets
European Society of Coloproctology
6 years
🚨#ESCP2020 Vilnius Announcement🚨 It is with sadness that today we announce the cancellation of our Annual Meeting in Vilnius. An update from President @WBemelman, General Secretary @GabrielaMoslein & Education Committee Chair @d_hahnd is shared below. https://t.co/dlgbVBdtvY
9
44
47